#asco26

Anya Rossi

sweetdream.ai

SweetDream.ai•Sponsored•Livecam

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Exclusive private shows

1.2k viewers online

Private Show

Join now for exclusive access

Free preview available • Premium content

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived #ASCO26

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived #ASCO26

Mark Lewis, MD, FASCO

1,169,633 views • 1 month ago

This is not simply a new pancreatic cancer drug. It is a reminder that even “undruggable” biology can become treatable with persistence. Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months. A remarkable ASCO moment. #ASCO26 Toni Choueiri, MD Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) Dr. Cathy Eng Sumanta K. Pal, MD, FASCO Tom Powles Brian Rini, MD Daniel Castellano gilberto lopes Petros Grivas Dra. María Natalia Gandur Quiroga Emre Yekedüz Neeraj Agarwal, MD, FASCO ASCO ONCOassist® | The go-to oncology app Open Medicine Kate Sears Simon C 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 UroToday.com OncLive.com Cristiane D Bergerot, PhD, FASCO International Urology Cancer Summit Dr Amol Akhade LARVOL IMG Oncologists

This is not simply a new pancreatic cancer drug. It is a reminder that even “undruggable” biology can become treatable with persistence. Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months. A remarkable ASCO moment. #ASCO26 Toni Choueiri, MD Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) Dr. Cathy Eng Sumanta K. Pal, MD, FASCO Tom Powles Brian Rini, MD Daniel Castellano gilberto lopes Petros Grivas Dra. María Natalia Gandur Quiroga Emre Yekedüz Neeraj Agarwal, MD, FASCO ASCO ONCOassist® | The go-to oncology app Open Medicine Kate Sears Simon C 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 UroToday.com OncLive.com Cristiane D Bergerot, PhD, FASCO International Urology Cancer Summit Dr Amol Akhade LARVOL IMG Oncologists

195,828 views • 1 month ago

Absolutely practice changing!! One of the most stunning developments in the treatment of patients with metastatic pancreatic cancer !! It is one of the rare moments in oncology which you will always remember ! Like the imatinib, trastuzumab presentations ASCO #ASCO26 OncoAlert

Absolutely practice changing!! One of the most stunning developments in the treatment of patients with metastatic pancreatic cancer !! It is one of the rare moments in oncology which you will always remember ! Like the imatinib, trastuzumab presentations ASCO #ASCO26 OncoAlert

Jame Abraham, MD, FACP

105,168 views • 1 month ago

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer. In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy. While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers. As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.” Congratulations to the researchers and patients who made this important progress possible. 👏👏👏 Video Courtesy: ASCO

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer. In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy. While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers. As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.” Congratulations to the researchers and patients who made this important progress possible. 👏👏👏 Video Courtesy: ASCO

52,509 views • 1 month ago

My last interview of #ASCO26 - with Celcuity CEO Brian Sullivan. It’s a tough business when your stock trades down 25% after landing a .50 hazard ratio against the standard of care.

My last interview of #ASCO26 - with Celcuity CEO Brian Sullivan. It’s a tough business when your stock trades down 25% after landing a .50 hazard ratio against the standard of care.

34,284 views • 1 month ago

This is a historic data release. A real advance for pancreatic cancer patients, and it shows that our industry goes after the hardest things and can win. #ASCO26

This is a historic data release. A real advance for pancreatic cancer patients, and it shows that our industry goes after the hardest things and can win. #ASCO26

25,954 views • 1 month ago

#ASCO26 truly embodied the theme of translating science into global patient outcomes. We are grateful to the ~46,000 attendees, all working tirelessly to conquer cancer together! A heartfelt thanks to all. 💗 We can’t wait to see you next year at #ASCO27!

#ASCO26 truly embodied the theme of translating science into global patient outcomes. We are grateful to the ~46,000 attendees, all working tirelessly to conquer cancer together! A heartfelt thanks to all. 💗 We can’t wait to see you next year at #ASCO27!

20,990 views • 1 month ago

Lung Cancer Conference Highlights from #ASCO26 w/ Isabel Preeshagul ✅ #LIBRETTO432 ✅ #CROWN (& LORIN) ✅ #CHRYSALIS2 ✅ #HARMONi6 ✅ A quick mention about DeLLphi304 Full 🗣️ ⭐️ OncBrothers & OncUpdates website ⭐️“Oncology Brothers” podcast #OncTwitter #lcsm #MedTwitter

Lung Cancer Conference Highlights from #ASCO26 w/ Isabel Preeshagul ✅ #LIBRETTO432 ✅ #CROWN (& LORIN) ✅ #CHRYSALIS2 ✅ #HARMONi6 ✅ A quick mention about DeLLphi304 Full 🗣️ ⭐️ OncBrothers & OncUpdates website ⭐️“Oncology Brothers” podcast #OncTwitter #lcsm #MedTwitter

Oncology Brothers

15,115 views • 1 month ago

GI Malignancies Conference Highlights from #ASCO26 w/ Namrata (Neena) Vijayvergia MD ✅ #EMERALD3 ✅ #FIGHT302 ✅ #CIRCULATE ✅ #MATTERHORN Full 🗣️ ⭐️ “Oncology Brothers” podcast ⭐️ #OncTwitter #MedTwitter #gism OncUpdates

GI Malignancies Conference Highlights from #ASCO26 w/ Namrata (Neena) Vijayvergia MD ✅ #EMERALD3 ✅ #FIGHT302 ✅ #CIRCULATE ✅ #MATTERHORN Full 🗣️ ⭐️ “Oncology Brothers” podcast ⭐️ #OncTwitter #MedTwitter #gism OncUpdates

Oncology Brothers

12,000 views • 1 month ago

Today at #ASCO26, in collaboration with Moderna, we're proud to present five-year follow-up results from a Phase 2b study evaluating our investigational individualized neoantigen therapy for #melanoma. Learn more:

Today at #ASCO26, in collaboration with Moderna, we're proud to present five-year follow-up results from a Phase 2b study evaluating our investigational individualized neoantigen therapy for #melanoma. Learn more:

13,886 views • 1 month ago

Witnessed the arrival of a potential game changer👀 #ASCO26 Plenary Session 🔥 RASolute 302 in RAS G12D–mutant pancreatic cancer Daraxonrasib showed a striking OS benefit vs chemotherapy: ✅ mOS 13.2 vs 6.6 months, HR 0.40 ✅ 12-mo OS 53.3% vs 18.7%

Witnessed the arrival of a potential game changer👀 #ASCO26 Plenary Session 🔥 RASolute 302 in RAS G12D–mutant pancreatic cancer Daraxonrasib showed a striking OS benefit vs chemotherapy: ✅ mOS 13.2 vs 6.6 months, HR 0.40 ✅ 12-mo OS 53.3% vs 18.7%

Masahiro TORASAWA, MD. PhD.

12,773 views • 1 month ago

We’re presenting new data at #ASCO26 from our robust oncology portfolio and pipeline across earlier-stage and advanced tumor types. We’re focused on advancing research to fight cancer and evaluate new approaches to help prolong and protect lives. Learn more:

We’re presenting new data at #ASCO26 from our robust oncology portfolio and pipeline across earlier-stage and advanced tumor types. We’re focused on advancing research to fight cancer and evaluate new approaches to help prolong and protect lives. Learn more:

15,734 views • 2 months ago